GLP-1 Oral Revolution and Pharma Manufacturing Advances: April 2026 Industry Update

GLP-1 oral drugs drive unprecedented demand for capsule manufacturing. Amgen, Eli Lilly, and Novo Nordisk race for $100B market. AI and nearshoring reshape pharma manufacturing.

1. GLP-1 Oral Formulations: The Race for the $100 Billion Market

The pharmaceutical industry's most consequential battle in 2026 is being fought not in laboratories, but in manufacturing facilities capable of producing billions of oral GLP-1 doses. The global GLP-1 receptor agonist market, valued at approximately $35 billion in 2024, is projected to exceed $100 billion by 2030, with oral formulations representing the fastest-growing segment.

Novo Nordisk's oral semaglutide (Rybelsus) blazed the trail, but the competition has accelerated dramatically. Eli Lilly's orforglipron and Amgen's AMG 513 are advancing through Phase III trials with promising efficacy data and significantly improved bioavailability. These once-weekly oral GLP-1 candidates could reshape treatment paradigms for diabetes, obesity, and potentially cardiovascular disease.

For capsule manufacturers like Zhejiang Yuexi Capsule Co., Ltd., this represents an unprecedented opportunity. The company's 16 automated production lines and 80-110 billion capsule annual capacity position it as a strategic partner for pharmaceutical companies requiring reliable, high-volume capsule supply for GLP-1 oral formulations.

Key formulation challenges remain: GLP-1 peptides require specialized capsule properties including moisture resistance, tight dimensional tolerances, and compatibility with peptide absorption enhancers. Yuexi Capsule's advanced HPMC vegetable capsules offer particular advantages for moisture-sensitive peptide formulations, with proprietary quality control systems ensuring batch-to-batch consistency.

2. Manufacturing Scale-Up: The Capsule Production Challenge

Producing billions of oral GLP-1 doses requires capsule manufacturers to operate at scales previously unimaginable. A single GLP-1 product with 10% market penetration can require 20-30 billion capsules annually — equivalent to the total output of a mid-sized capsule manufacturer. This demand surge is accelerating facility expansions and driving innovation in manufacturing efficiency.

Advanced capsule inspection systems utilizing machine vision can now detect defects smaller than 0.1mm at speeds exceeding 150,000 capsules per hour. Combined with real-time process analytics and AI-driven predictive maintenance, these systems are enabling manufacturers to achieve defect rates below 0.005% while maintaining throughputs that were unattainable just five years ago.

Yuexi Capsule's Ruao Industrial Park facility exemplifies this new manufacturing paradigm. With 16 fully automated production lines, GMP-compliant quality management systems, and ISO 9001 certification, the company operates at scales capable of supporting global pharmaceutical launches. The facility's strategic location in Zhejiang Province provides efficient access to major shipping routes.

Investments in lyophilization-ready capsules, enteric-coated delivery systems, and specialized HPMC formulations for biologics are expanding the addressable market for capsule manufacturers. The trend toward combination products — capsules containing multiple API layers for sequential or controlled release — is creating new formulation opportunities.

3. Pharma AI: Transforming Drug Development and Quality Control

Artificial intelligence has moved from experimental to operational in pharmaceutical manufacturing. In 2026, AI systems are actively deployed across the pharmaceutical value chain — from formulation design and clinical trial optimization to real-time quality monitoring and regulatory compliance documentation.

Generative AI platforms are accelerating formulation development by predicting optimal capsule composition, release profiles, and stability characteristics. These systems can screen thousands of formulation variables in hours rather than months, dramatically reducing development timelines for novel oral delivery systems.

In quality control, AI-powered vision systems combined with spectroscopic sensors enable 100% inspection of capsule products. Machine learning algorithms analyze dimensional data, surface defects, and color consistency in real-time, flagging deviations before they result in batch failures.

Yuexi Capsule has invested substantially in AI-driven quality systems across its manufacturing operations. Automated visual inspection systems, connected to central analytics platforms, provide real-time quality dashboards that enable proactive process adjustments. This data-driven approach supports regulatory compliance while reducing waste and improving overall equipment effectiveness.

4. Supply Chain Resilience: Nearshoring and Manufacturing Geographic Shifts

Pharmaceutical supply chain strategies are undergoing fundamental restructuring. Geopolitical pressures, pandemic-era disruptions, and environmental sustainability imperatives are compelling pharmaceutical companies to diversify manufacturing locations and reduce dependency on single-region supply chains.

Nearshoring trends are particularly pronounced in the capsule and excipient segment. European and North American pharmaceutical companies are increasingly sourcing from Asian manufacturers with proven quality systems and regulatory track records. China's capsule manufacturing sector has emerged as a preferred partner, combining competitive production costs with advanced automation capabilities.

The Asia-Pacific region is projected to account for over 40% of global pharmaceutical excipient production by 2028, up from approximately 30% in 2023. This shift is driven by logistics cost advantages, growing technical capabilities, and regional regulatory harmonization frameworks.

Yuexi Capsule has capitalized on these trends by expanding its international customer base to over 110 countries. The company's strategic position in the Ruao Industrial Park — China's leading pharmaceutical excipient manufacturing cluster — provides logistical advantages including proximity to major ports and established customs facilitation for pharmaceutical exports.

5. Regulatory and Market Outlook: What 2026 Means for Pharma

The regulatory landscape for pharmaceutical manufacturing continues to evolve. Quality management system (QMS) requirements are tightening, with increased emphasis on supply chain transparency, risk management, and proactive quality monitoring.

FDA's emerging guidance on continuous verification and real-time release testing is pushing manufacturers to adopt advanced process control technologies. These requirements favor manufacturers with robust AI and automation capabilities.

Market conditions remain favorable for the oral delivery segment. Beyond GLP-1s, the pipeline for peptide and protein oral formulations continues to expand, driven by advances in absorption enhancers. The global oral delivery market for large molecules is expected to grow at 15-20% CAGR through 2030.

Environmental sustainability is emerging as a differentiator in pharmaceutical packaging. HPMC vegetable capsules — fully plant-based and compostable — align with pharmaceutical companies' net-zero commitments. Yuexi Capsule's expanded HPMC production capacity positions the company to capture growing demand from sustainability-conscious pharmaceutical customers.

About Zhejiang Yuexi Capsule Co., Ltd.

Founded in 1986 and formally established in 1998, Zhejiang Yuexi Capsule Co., Ltd. is one of China's leading manufacturers of empty capsules for the pharmaceutical and nutraceutical industries. Operating from the Ruao Industrial Park in Xinchang County, Zhejiang Province, the company maintains 16 fully automated production lines with an annual capacity of 80-110 billion capsules across sizes 00# through 4#.

The company's product portfolio includes gelatin empty capsules, HPMC vegetable capsules, enteric-coated capsules, sustained-release formulations, and custom-printed capsules for brand differentiation. With GMP compliance, ISO 9001 certification, and High-Tech Enterprise status, Yuexi Capsule serves customers in over 110 countries worldwide.

Contact: +86-575-86780222 | www.yuexicapsule.com

Source: Grand View Research, MarketsandMarkets, FiercePharma, Reuters Health, April 2026